DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infections, Intestinal

Intervention: Drug: GSK2251052 (Drug); Meropenem (Drug); Placebo (Other)

Phase: Phase 2

Status: Terminated

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline

Summary

This study is being conducted to evaluate the safety, efficacy and pharmacokinetics/pharmacodynamics of GSK2251052 in subjects with complicated intra abdominal infections. GSK2251052 will be compared to meropenem, an IV therapy that is approved for use in the treatment of subjects with cIAI. GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for cIAI.

Clinical Details

Official title: A Prospective, Randomized, Double-blind, Multi-center, Dose-ranging Study of the Safety, Tolerability and Efficacy of GSK2251052 in the Treatment of Complicated Intra-abdominal Infections in Adults

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome:

Safety outcome - On Therapy

Safety outcome - End of Therapy

Safety outcome - Test of Cure

Safety outcome - Early Follow-up

Safety outcome - Follow-up

Efficacy outcome - clinical response

Safety outcome at Hematology Safety Visit

Secondary outcome:

Microbiological response

Clinical response

Therapeutic response

Maximum plasma concentration (Cmax) of GSK2251052

Area under the concentration time curve (AUC) of GSK2251052

Time to Cmax (Tmax) of GSK2251052

Cmax of GSK2251052 using Non-intensive PK sampling

AUC of GSK2251052 using Non-intensive PK sampling

Tmax of GSK2251052 using Non-intensive PK sampling

Cmax of GSK2251052 using intensive PK sampling

AUC of GSK2251052 using intensive PK sampling

Tmax of GSK2251052 using intensive PK sampling

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adult subjects least 18 years of age.

N. B. Females of non-childbearing or childbearing potential may be enrolled. It is not contraindicated to enrol females of childbearing potential; however, females of childbearing potential must have a negative pregnancy test at study entry and must have practiced adequate contraception for at least 30 days prior to study entry. Additionally, the subject agrees to one of the following methods for avoidance of pregnancy during the entire study treatment period:

- Abstinence; or,

- Oral Contraceptive, either combined estrogen/progesterone or progesterone alone, PLUS

an additional barrier method [ie, condom, occlusive cap (diaphragm or cervical/vault caps) or vaginal spermicidal agent (foam/gel/film/cream/suppository)]; or,

- Injectable progesterone; or

- Implants of levonorgestrel; or,

- Estrogenic vaginal ring; or,

- Percutaneous contraceptive patches; or

- Intrauterine device (IUD) or intrauterine system (IUS) showing that failure rate is

less than 1% in the IUD or IUS product label; or,

- Has a male partner who is sterilized (vasectomy with documentation of azoospermia).

- Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps)

with a vaginal spermicidal agent (foam/gel/film/cream/suppository)

- Females are considered to be of non-childbearing potential if they have documented

tubal ligation or hysterectomy; or are postmenopausal, defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<147 pmol/L) is confirmatory]

- Subject has evidence of a systemic inflammatory response believed to be related to an

intra-abdominal infectious process with no evidence of another infectious source (e. g., catheter related, lung, urinary tract)

- Subject has an abnormal white blood cell count (>12,000/µL or <4,000/µL or >10%

bands) PLUS one or more of the following

- Fever, defined as >38°C oral, >38. 5°C tympanic or >39°C rectal, within the last 24

hours

- Heart rate of more than 90 beats per minute

- Respiratory rate of more than 20 breaths per minute or a PaCO2 level of less than 32

mm Hg

- Altered mental status thought due to an infectious process

- Subject is post-op and required surgery within the last 24 hours prior to first dose

of study medication OR subject requires surgical intervention (e. g., laparotomy, laparoscopic surgery, or percutaneous drainage of an abscess) within 24 hours of first dose of study medication with no more than one pre-surgical dose of an antibiotic given for pre-operative prophylaxis.

- Subject has a known Gram-negative pathogen(s) isolated prior to study entry or a

suspected Gram-negative post-operative infection or has failed a prior Gram negative treatment regimen A subject enrolled as a failure of a previous antibacterial treatment regimen must: Show lack of improvement or worsening in signs and symptoms of infection, including continued or worsening peritoneal findings Require additional surgical intervention which must be performed within 24 hours of first dose of study medication with no more than one pre-surgical dose of an antibiotic given for pre-operative prophylaxis AND/OR Be post-op and have required surgery within 24 hours prior to first dose of study medication with no more than one pre-surgical dose of an antibiotic given for pre-operative prophylaxis. Have a culture positive for a Gram-negative pathogen (from an intra-abdominal site) N. B. Such subjects may be enrolled before the results of the culture are known but if the culture is negative, the subject must be removed from study drug therapy.

- Subject requires antibacterial therapy for an anticipated duration of 7 days or more,

in addition to surgical intervention, for one of the following eligible diagnoses:

- Cholecystitis (including gangrenous cholecystitis) with rupture, perforation or

progression of the infection beyond the gallbladder wall

- Diverticular disease with perforation or abscess

- Appendiceal perforation with duration of symptoms >=48 hours AND imaging that is

strongly suggestive of free fluid or abscess

- Acute gastric and duodenal perforations, only if operated more than 24 hours after

perforation occurred

- Traumatic perforation of the intestine only if operated more than 12 hours after

perforation occurred

- Peritonitis due to perforated viscus, post-operative, or other focus of infection

(but not spontaneous bacterial peritonitis associated with cirrhosis and chronic ascites)

- Inflammatory bowel disease or ischemic bowel disease with bowel perforation

- If pre-operative, subject must have peritoneal findings highly suspicious for cIAI,

defined as one or more of the following:

- Abdominal pain and/or tenderness

- Localized or diffuse abdominal wall rigidity

- An imaging procedure, ie. ultrasound or CT scan showing evidence of IAI

- Mass

- Ileus

- QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block

Exclusion Criteria:

- Subject has a known or suspected diagnosis of the following:

- Abdominal wall abscess

- Small bowel obstruction or ischemic bowel disease without perforation

- Traumatic bowel perforation with surgery within 12 hours

- Perforation of gastroduodenal ulcer with surgery within 24 hours

- Any other intra-abdominal processes in which the primary etiology is not likely to be

infectious.

- Simple cholecystitis

- Gangrenous or suppurative cholecystitis without rupture or extension beyond the

gallbladder wall

- Simple appendicitis

- Acute suppurative cholangitis

- Infected, necrotizing pancreatitis, or pancreatic abscess

- Subject must not be managed by staged abdominal repair or open abdominal technique

- Subject is known at study entry, prior to randomization to study medication, to have

a cIAI caused by a Gram-positive pathogen or a pathogen resistant to the study antimicrobial agent.

- Subject has an APACHE II score >20.

- Subject is considered unlikely to survive the 4 6 week study period or has any

rapidly progressing disease or immediately life-threatening illness (including acute hepatic failure, respiratory failure or septic shock).

- Subject requires treatment with concomitant systemic antibacterial agents other than

vancomycin.

- Subject has moderate to severe impairment of renal function including a calculated

creatinine clearance (CrCl) of less than 50 mL/min; requirement for peritoneal dialysis, hemodialysis, or hemofiltration; or oliguria (less than 20 mL urine output per hour over 24 hours).

- Subject has a prior history of seizures or CNS abnormality and/or is using

concomitant medications with seizure potential

- Subject requires probenecid or valproic acid medications

- Subject has evidence of known or pre-existing severe hepatic disease(Child-Pugh score

of B or C)

- Subject has a known baseline hemoglobin less than 10 g/dL ,hematocrit less than 30%

and/or a known reticulocyte count of >5% (ie, reticulocytes >5% of total RBC mass)

- Subject has known neutropenia or is anticipated to develop neutropenia during the

course of the study (ie, new chemotherapy patient), with absolute neutrophil count less than 1000 cells/mm3

- Subject has a known platelet count less than 75,000 cells /mm3 (subjects with

platelet counts as low as 50,000 cells /mm3 are eligible if the reduction is historically stable)

- Subject has an immunocompromising illness; including known human immunodeficiency

virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), organ (including bone marrow) transplant recipients, and hematological malignancy, and immunosuppressive therapy , including high-dose corticosteroids (e. g., greater than 40mg prednisone or equivalent per day for greater than two weeks)

- Subject has participated in any investigational drug or device study within 30 days

of study entry or within 5 half-lives, whichever is longer.

- Subject has had more than 24 hours of systemic antibacterial therapy for cIAI within

the 48 hour period prior to first dose of IV study drug therapy, unless there is a documented lack of clinical response to such therapy

- Subject has a history of moderate or severe hypersensitivity to Meropenem or to

beta-lactam antibiotics

- Subject has previously received treatment with GSK2251052

- Subject is pregnant or nursing.

- Subject, in the opinion of the investigator, may be significantly compromised by a

potential drop in haemoglobin greater than 2. 5g/dl which is not related to the condition under study

- French subjects: the French subject has participated in any study using an

investigational drug during the previous 30 days.

Locations and Contacts

GSK Investigational Site, Praha 10 100 34, Czech Republic

GSK Investigational Site, Praha 10 10034, Czech Republic

GSK Investigational Site, Limoges 87042, France

GSK Investigational Site, Nîmes cedex 9 30029, France

GSK Investigational Site, Strasbourg 67200, France

GSK Investigational Site, Irkutsk 664079, Russian Federation

GSK Investigational Site, Perm 614036, Russian Federation

GSK Investigational Site, Perm 614068, Russian Federation

GSK Investigational Site, Smolensk 214019, Russian Federation

GSK Investigational Site, St. Petersburgh 192242, Russian Federation

GSK Investigational Site, Alicante 03010, Spain

GSK Investigational Site, Elche (Alicante) 03203, Spain

GSK Investigational Site, Madrid 28006, Spain

GSK Investigational Site, Pama de Mallorca 07010, Spain

GSK Investigational Site, Mobile, Alabama 36617, United States

GSK Investigational Site, Long Beach, California 90822, United States

GSK Investigational Site, Torrance, California 90509, United States

GSK Investigational Site, Jacksonville, Florida 32209, United States

GSK Investigational Site, Council Bluffs, Iowa 51503, United States

GSK Investigational Site, Topeka, Kansas 66604, United States

GSK Investigational Site, New Orleans, Louisiana 70112, United States

GSK Investigational Site, Las Vegas, Nevada 89109, United States

GSK Investigational Site, Buffalo, New York 14215, United States

GSK Investigational Site, Columbus, Ohio 43215, United States

GSK Investigational Site, Lima, Ohio 45801, United States

GSK Investigational Site, Chicoutimi, Quebec G7H 5H6, Canada

GSK Investigational Site, Sherbrooke, Quebec J1H 5N4, Canada

GSK Investigational Site, Trois-Rivières, Quebec G8Z 3R9, Canada

GSK Investigational Site, Saskatoon, Saskatchewan S7N 0W8, Canada

GSK Investigational Site, Verona, Veneto 37134, Italy

GSK Investigational Site, Richmond, Virginia 23298, United States

Additional Information

Starting date: October 2011
Last updated: July 24, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017